BR0210077A - Composto, seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa - Google Patents
Composto, seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfaInfo
- Publication number
- BR0210077A BR0210077A BR0210077-0A BR0210077A BR0210077A BR 0210077 A BR0210077 A BR 0210077A BR 0210077 A BR0210077 A BR 0210077A BR 0210077 A BR0210077 A BR 0210077A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- alkyl
- solvates
- pharmaceutically acceptable
- esters
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 150000002148 esters Chemical class 0.000 title abstract 3
- 239000012453 solvate Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"COMPOSTO, SEUS SAIS, SOLVATOS E éSTERES HIDROLISáVEIS FARMACEUTICAMENTE ACEITáVEIS COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODO DE TRATAMENTO DE UMA DOENçA OU CONDIçãO MEDIADA POR HPPAR ALFA". Um composto de fórmula (I) e sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis deste, em que R^ 1^ e R^ 2^ são independentemente H ou alquila C~ 1-3~ ou R^ 1^ e R^ 2^ que são ligados ao mesmo átomo de carbono podem juntamente com o átomo de carbono a qual eles são ligados formar um anel de cicloalquila de 3 a 5 membros; X~ 1~ representa O ou S; cada R^ 3^, R^ 4^, R^ 8^ e R^ 9~ independentemente representa H, halogênio, -CH~ 3~ e OCH~ 3~; R^ 5^ representa H ou alquila C~ 1-6~ ou R~ 4~ e R^ 5^ juntos formam um anel de cicloalquila de 3 a 6 membros. X~ 2~ representa NH, NCH~ 3~ ou O; um de Y e Z é N, e o outro é O ou S; R^ 6^ representa fenila ou piridila (em que N está na posição 2 ou 3) e é opcionalmente substituído por um ou mais halogênio, CF~ 3~, alquila C~ 1-6~ reta ou ramificada (opcionalmente substituída por halogênio), com a condição de que quando R^ 6^ for piridila, o N é não substituível. R^ 7^ representa alquila C~ 1-6~, (opcionalmente substituída por um ou mais halogênios), alquila C~ 0-6~-heteroarila de 5 membros, alquila C~ 0-6~ (O)~ n~-fenila, em que n é 0 ou 1, com a condição de que quando R^ 1^ e R^ 2^ forem metila, R^ 8^ e R^ 9^ forem H, R^ 5^ for H, então R^ 7^ não pode ser CH~ 3~ ou CF~ 3~.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0113233.1A GB0113233D0 (en) | 2001-05-31 | 2001-05-31 | Chemical compounds |
| PCT/EP2002/005885 WO2002096894A1 (en) | 2001-05-31 | 2002-05-29 | Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0210077A true BR0210077A (pt) | 2004-06-22 |
Family
ID=9915638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0210077-0A BR0210077A (pt) | 2001-05-31 | 2002-05-29 | Composto, seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6867225B2 (pt) |
| EP (1) | EP1392665B1 (pt) |
| JP (1) | JP2004532266A (pt) |
| KR (1) | KR20040007633A (pt) |
| CN (1) | CN1529698A (pt) |
| AT (1) | ATE377007T1 (pt) |
| AU (1) | AU2002312954B2 (pt) |
| BR (1) | BR0210077A (pt) |
| CA (1) | CA2448103A1 (pt) |
| CO (1) | CO5540299A2 (pt) |
| CZ (1) | CZ20033250A3 (pt) |
| DE (1) | DE60223245T2 (pt) |
| ES (1) | ES2295352T3 (pt) |
| GB (1) | GB0113233D0 (pt) |
| HU (1) | HUP0400056A2 (pt) |
| IL (1) | IL158818A0 (pt) |
| MX (1) | MXPA03010584A (pt) |
| NO (1) | NO20035316L (pt) |
| PL (1) | PL367215A1 (pt) |
| WO (1) | WO2002096894A1 (pt) |
| ZA (1) | ZA200308864B (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| GB0113232D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical process |
| GB0113231D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
| JP2006502134A (ja) * | 2002-08-09 | 2006-01-19 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体において活性を有する化合物 |
| WO2004022551A1 (ja) | 2002-09-06 | 2004-03-18 | Takeda Pharmaceutical Company Limited | フランまたはチオフェン誘導体およびその医薬用途 |
| GB0314370D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| US20050203151A1 (en) * | 2003-12-19 | 2005-09-15 | Kalypsys, Inc. | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions |
| FR2866339B1 (fr) * | 2004-02-18 | 2006-05-05 | Pf Medicament | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| DE102004051277A1 (de) * | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| FR2882359A1 (fr) * | 2005-02-24 | 2006-08-25 | Negma Lerads Soc Par Actions S | Derives activateurs de ppar, procede de preparation et application en therapeutique |
| FR2882750B1 (fr) * | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| JP5225076B2 (ja) * | 2006-04-27 | 2013-07-03 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体の医薬用途 |
| FR2901792A1 (fr) * | 2006-06-06 | 2007-12-07 | Negma Lerads Soc Par Actions S | DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE |
| WO2008035359A2 (en) * | 2006-06-12 | 2008-03-27 | Cadila Healthcare Limited | Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| TW201022221A (en) | 2008-12-01 | 2010-06-16 | Mitsubishi Tanabe Pharma Corp | Carboxylic acid derivatives containing thiazole ring and pharmaceutical use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859051A (en) | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
| US6207422B1 (en) * | 1998-04-17 | 2001-03-27 | The Metrohealth System | Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same |
| WO2000018903A2 (en) * | 1998-09-29 | 2000-04-06 | The Johns Hopkins University | Inducible genetic suppression of cellular excitability |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| AU2002233271A1 (en) | 2000-12-20 | 2002-07-01 | Glaxo Group Limited | Substitued oxazoles and thiazoles as hppar alpha agonists |
-
2001
- 2001-05-31 GB GBGB0113233.1A patent/GB0113233D0/en not_active Ceased
-
2002
- 2002-05-29 EP EP02738123A patent/EP1392665B1/en not_active Expired - Lifetime
- 2002-05-29 PL PL02367215A patent/PL367215A1/xx not_active Application Discontinuation
- 2002-05-29 JP JP2003500073A patent/JP2004532266A/ja active Pending
- 2002-05-29 CZ CZ20033250A patent/CZ20033250A3/cs unknown
- 2002-05-29 CA CA002448103A patent/CA2448103A1/en not_active Abandoned
- 2002-05-29 CN CNA028110803A patent/CN1529698A/zh active Pending
- 2002-05-29 KR KR10-2003-7015688A patent/KR20040007633A/ko not_active Application Discontinuation
- 2002-05-29 IL IL15881802A patent/IL158818A0/xx unknown
- 2002-05-29 HU HU0400056A patent/HUP0400056A2/hu unknown
- 2002-05-29 BR BR0210077-0A patent/BR0210077A/pt not_active IP Right Cessation
- 2002-05-29 AU AU2002312954A patent/AU2002312954B2/en not_active Ceased
- 2002-05-29 MX MXPA03010584A patent/MXPA03010584A/es unknown
- 2002-05-29 AT AT02738123T patent/ATE377007T1/de not_active IP Right Cessation
- 2002-05-29 ES ES02738123T patent/ES2295352T3/es not_active Expired - Lifetime
- 2002-05-29 US US10/478,259 patent/US6867225B2/en not_active Expired - Fee Related
- 2002-05-29 WO PCT/EP2002/005885 patent/WO2002096894A1/en not_active Application Discontinuation
- 2002-05-29 DE DE60223245T patent/DE60223245T2/de not_active Expired - Fee Related
-
2003
- 2003-11-13 ZA ZA200308864A patent/ZA200308864B/en unknown
- 2003-11-28 NO NO20035316A patent/NO20035316L/no not_active Application Discontinuation
- 2003-12-02 CO CO03106071A patent/CO5540299A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2448103A1 (en) | 2002-12-05 |
| US20040176427A1 (en) | 2004-09-09 |
| HUP0400056A2 (hu) | 2004-04-28 |
| DE60223245D1 (de) | 2007-12-13 |
| CO5540299A2 (es) | 2005-07-29 |
| ZA200308864B (en) | 2005-02-14 |
| KR20040007633A (ko) | 2004-01-24 |
| WO2002096894A1 (en) | 2002-12-05 |
| CZ20033250A3 (en) | 2004-03-17 |
| GB0113233D0 (en) | 2001-07-25 |
| AU2002312954B2 (en) | 2004-12-02 |
| JP2004532266A (ja) | 2004-10-21 |
| ATE377007T1 (de) | 2007-11-15 |
| EP1392665B1 (en) | 2007-10-31 |
| NO20035316D0 (no) | 2003-11-28 |
| MXPA03010584A (es) | 2004-03-09 |
| CN1529698A (zh) | 2004-09-15 |
| EP1392665A1 (en) | 2004-03-03 |
| IL158818A0 (en) | 2004-05-12 |
| ES2295352T3 (es) | 2008-04-16 |
| PL367215A1 (en) | 2005-02-21 |
| NO20035316L (no) | 2003-11-28 |
| US6867225B2 (en) | 2005-03-15 |
| DE60223245T2 (de) | 2008-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0210077A (pt) | Composto, seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa | |
| BR0016067A (pt) | Oxazóis substituìdos e derivados tiazóis como ativadores de hppar alfa | |
| DE69007429D1 (de) | Isoindolonderivate, ihre Herstellung und diese enthaltende pharmazeutische Zusammensetzungen. | |
| IS6565A (is) | Trópan afleiður nytsamlegar í meðferð | |
| DK0565549T3 (da) | Anvendelse af 1,3-oxathiolannucleosidanaloger til fremstilling af et præparat til behandling af hepatitis B | |
| MX9202287A (es) | Nuevos derivados de perhidroisoindol, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| NO20025821L (no) | 2-aminokarbonyl-9H-purinderivater | |
| FI915970A0 (fi) | Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper. | |
| NO166129C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler. | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| IT1311922B1 (it) | Composti farmaceutici. | |
| EA200000614A1 (ru) | 2,3-замещенные соединения индола в качестве ингибиторов сох-2 | |
| DE60239170D1 (de) | Bicyclische Verbindungen | |
| BR0209785A (pt) | Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um paciente | |
| NO972887L (no) | Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel | |
| DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
| DK231189A (da) | Fungicide forbindelser, fremgangsmaade til fremstilling deraf, fungicide midler indeholdende disse samt anvendelse deraf | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
| DK406587D0 (da) | 1,4-dihydropyridinderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse | |
| ATE145911T1 (de) | Inositol-phosphat-analog als kalzium- antagonistische substanz | |
| NO157655C (no) | Analogifremgangsmaate for fremstilling av farmakologisk aktive tiazolderivater. | |
| NO20075505L (no) | 7-fluor-1,3-dihydro-indol-2-on oksazolidinoner som antibakterielle forbindelser | |
| BR0302137A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma condição ou doença mediada por hppar em um paciente | |
| HUP0302576A2 (hu) | Fungicid keverékek | |
| DK1065206T3 (da) | Tetrazolylalkylindol-forbindelser som anti-inflammatoriske og analgetiske midler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |